In situ photoimmunotherapy: a tumour‐directed treatment for melanoma
暂无分享,去创建一个
R. Nordquist | W. Chen | M. Naylor | T. Teague | L. A. Perry | W.R. Chen | T.K. Teague | M. F. Naylor | Wei R. Chen | T. K. Teague
[1] F. Hodi,et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute , 2005, Melanoma research.
[2] P. Lambert,et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. , 2004, Vaccine.
[3] C. Cooper,et al. CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study , 2004, Journal of Clinical Immunology.
[4] S. Wagner,et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. , 2004, The Journal of investigative dermatology.
[5] D. Persing,et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents , 2004, Expert opinion on biological therapy.
[6] B. Pulendran. Modulating vaccine responses with dendritic cells and Toll‐like receptors , 2004, Immunological reviews.
[7] J. Thomas,et al. Management of in‐transit metastases from cutaneous malignant melanoma , 2004, The British journal of surgery.
[8] A. Veyre,et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases , 2004, The British journal of dermatology.
[9] D. Golenbock,et al. Haemophilus influenzae Type b-Outer Membrane Protein Complex Glycoconjugate Vaccine Induces Cytokine Production by Engaging Human Toll-Like Receptor 2 (TLR2) and Requires the Presence of TLR2 for Optimal Immunogenicity1 , 2004, The Journal of Immunology.
[10] H. Kerl,et al. Locoregional Cutaneous Metastases of Malignant Melanoma and their Management , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[11] T. Luger,et al. Imiquimod, pegyliertes Interferon-α-2b und Interleukin-2 in der Behandlung kutaner Melanommetastasen , 2004, Der Hautarzt.
[12] Hong Liu,et al. Induced antitumor immunity against DMBA‐4 metastatic mammary tumors in rats using laser immunotherapy , 2003, International journal of cancer.
[13] A. Awada,et al. Management of Cutaneous Locoregional Recurrences of Melanoma: A New Therapeutic Perspective with Imiquimod , 2003, Dermatology.
[14] B. Bonnekoh,et al. Imiquimod, a Topical Immune Response Modifier, in the Treatment of Cutaneous Metastases of Malignant Melanoma , 2002, Dermatology.
[15] Martin F. Mihm,et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. Schuler,et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. , 2000, Journal of the American Academy of Dermatology.
[17] Martin F. Mihm,et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma , 2000, Cancer.
[18] Wei R. Chen,et al. Long‐term tumor resistance induced by laser photo‐immunotherapy , 1999, International journal of cancer.
[19] Brown Tj,et al. Malignant melanoma: a clinical review. , 1999 .
[20] C. Loquai,et al. [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases]. , 2004, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[21] R. Nordquist,et al. Antitumor immunity induced by laser immunotherapy and its adoptive transfer. , 2001, Cancer research.
[22] B. Nelson,et al. Malignant melanoma: a clinical review. , 1999, Cutis.